
Tornado Cash Made Crypto Anonymous. Now One of Its Creators Faces Trial
Storm is one of the creators of Tornado Cash, a software tool for anonymizing crypto holdings. On July 14, the Kazakh-born developer will stand trial in the Southern District of New York, charged with conspiracy to commit money laundering and sanctions violations, and conspiracy to operate an unlicensed money transmitting business. If found guilty, he faces up to 45 years in prison.
Since the US Department of Justice charged Storm in 2023, his case has become a cause célèbre among crypto advocates. The DOJ alleges that Storm built and profited from a tool that allowed illicit actors—among them hackers with ties to North Korea—to launder at least $1 billion in crypto. But his supporters argue that all Storm did was publish code, an act of protected free speech.
'It's about the freedom to write code,' says Vitalik Buterin, cocreator of Ethereum, the blockchain network on which Tornado Cash runs. 'If the code-as-free-speech precedent is lost, that creates legal risk to people working on a pretty unbounded category of applications, and would create a pretty significant chilling effect.'
At trial, though, prosecutors will attempt to convince a jury that the case is far less fraught than all that. 'The government has not charged the defendant with a crime that involves solely writing code,' the DOJ claimed in an earlier court filing. 'The defendant in the case did much more,' the filing later says about that argument.
Storm and the DOJ both declined to be interviewed for this story.
Tornado Cash was created in 2019 by Storm and two other developers, Alexey Pertsev and Roman Semenov. The aim was to create a way to mask the ownership of crypto coins by interrupting the public trail of transactions recorded on a blockchain: Once deposited into Tornado Cash, coins belonging to many different parties are pooled, jumbled, and spat into brand new wallets, by which time it is no longer clear whose crypto is whose.
In May 2020, the founders made a change to the code that prevented anybody—themselves included—from modifying or disabling the underlying software, meaning Tornado Cash could operate independent of their involvement, court filings explain. But they maintained control over the website and interface through which the majority of Tornado Cash traffic passed. They also established a means of profiting by a corresponding crypto token, TORN, the value of which is roughly correlated to the amount of activity on Tornado Cash, prosecutors allege.
Services like Tornado Cash, sometimes described as mixers, are promoted by their advocates as a way to improve the level of privacy available to crypto users. 'We've basically sleepwalked into a world where every transaction is tracked by default,' says Buterin. 'We see privacy as something that should apply to money.' But crypto mixers have been readily co-opted for the purpose of money laundering, which has drawn the ire of governments.
On August 8, 2022, the Biden administration banned US citizens from using Tornado Cash. The service represented a "significant threat to [US] national security,' wrote the Treasury Department's Office of Foreign Assets Control, when it announced the sanctions. Tornado Cash had been used to launder billions of dollars worth of crypto, OFAC alleged, including $455 million stolen by the Lazarus Group, a cybercriminal operation sponsored by the state of North Korea.
Two days later, Pertsev was arrested by Dutch authorities. In a sort of preview of the arguments that will now play out in US court, Pertsev was tried in the Netherlands on money laundering charges. He was ultimately found guilty and sentenced to five years and four months in prison. (Pertsev is appealing the verdict.)
In August 2023, the DOJ brought charges against both Storm, who was arrested at his home near Seattle, and Semenov, who is currently wanted by the FBI. 'Claiming to offer the Tornado Cash service as a 'privacy service,' the defendants in fact knew that it was a haven for criminals to engage in large-scale money laundering and sanctions evasion,' the indictment alleged.
Under President Donald Trump, the US has performed an about-face in its attitude towards crypto enforcement, raising hopes among Storm's supporters that the charges against him might be dropped. Since Trump returned to the White House in January, his administration has pardoned crypto executives who had pleaded guilty to white collar offenses. In March, OFAC scrapped the sanctions imposed on Tornado Cash after a successful legal challenge by members of the crypto industry who argued the agency had overstepped its authority. The following month, deputy attorney general Todd Blanche announced that the DOJ would deprioritize certain crypto prosecutions, including failures to prevent money laundering and obtain money transmission licenses.
Nevertheless, the government will continue to pursue the criminal prosecution of Storm. 'This really is a vestige of the Biden administration's war on crypto,' claims Jake Chervinsky, chief legal officer at crypto VC firm Variant, who coauthored a court brief in support of Storm. 'It's shocking the case is still moving forward.'
The DOJ's decision to press onward might be interpreted as a signal of its confidence in its evidence—the full scope of which will only become clear at trial—and extent of the wrongdoing, says Joel Cohen, who leads the white collar practice at law firm White & Case.
'When prosecutors get down to the issue of proving a case, they're not thinking about how the case aligns with the department's philosophy,' says Cohen. 'When you get into battle, you fight like heck. That's what you do.'
The legal wranglings in the leadup to trial suggest that the prosecution and defense largely agree over the facts at hand: who developed Tornado Cash, its basic functions, and how it was abused by illicit actors. The trial will pivot on 'a fundamental disagreement about whether those facts add up to a criminal offense,' says Chervinsky.
A large portion of the trial, legal experts say, will focus on whether Storm intended for Tornado Cash to be used for illicit means, whether he knew that it was used to launder stolen funds, and whether he knew that inaction meant breaking the law, as prosecutors allege.
The defense will claim that the developers never intended that Tornado Cash be used to commit fraud, says Cohen. 'The prosecution will say that they should have known but stuck their heads in the sand,' he says.
The jury will also be presented with conflicting views as to how Tornado Cash was structured and operated, which could have a bearing on what rules Storm and the other developers were required to follow.
Government prosecutors contend that Tornado Cash was effectively run like any other for-profit business, irrespective of the founders relinquishing control of the underlying code. In the indictment, they argue that Storm was operating a money transmitter, which required him to collect identifying information about users that might have prevented Tornado Cash being abused to launder the proceeds of cybercrime.
The defense, meanwhile, has repeatedly emphasized the distance between Storm and the transactions that pass through Tornado Cash. Though the developers administered an optional user interface, at no point did they have custody of users' funds, they point out. Storm's supporters claim that the government's interpretation of money transmission law is without precedent.
'If publishing a software protocol for private transactions that people make on their own behalf is a crime in this country, then we've abandoned all of our First and Fourth Amendment principles that make this country great,' claims Peter Van Valkenburgh, executive director at crypto advocacy nonprofit Coin Center.
A guilty verdict, Storm has implied, could deal a potentially fatal blow to decentralized finance—the ambition in crypto circles to develop peer-to-peer financial services free from rent-seeking intermediaries and top-down control. 'If I lose, DeFi dies with me,' he wrote, in the June X post. 'The dream of financial freedom, the code I believed in—it all fades into darkness.'
The spillover effects could be even greater in scope, others have argued, resulting in a chilling of the entire software development industry. 'It's a referendum on the right to publish software. It's much broader than DeFi,' claims Van Valkenburgh. 'It's a referendum on whether you can perform the functions of a software developer and communications intermediary without facing unlimited criminal liability for sanctions, money laundering, and unlicensed money transmission.'
If Storm is liable for the abuse of Tornado Cash by illicit actors, his defenders ask, why isn't Linus Torvalds liable for criminality enabled by the Linux operating system, or Meta liable for criminal activity conducted over WhatsApp?
In the event of a guilty verdict, there is a high likelihood that these arguments will escalate to the appellate courts. Multiple Storm supporters say they prefer his chances in the Second Circuit, where judges—instead of a jury of peers—are tasked with rendering a cold and unemotional verdict on the application of the law.
'The government's theory cannot be correct and ultimately will be rejected by the courts, if not by a jury,' claims Chervinsky. 'The Supreme Court of the United States may be where we end up.'
For his part, Storm has cut a resolute and unrepentant figure as his trial date approaches. 'I do not have any regrets of my actions,' he said in a recent interview with the Crypto In America podcast. 'I wouldn't change anything I've done.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Trump pauses export controls to bolster China trade deal, FT says
(Reuters) -The U.S. has paused curbs on tech exports to China to avoid disrupting trade talks with Beijing and support President Donald Trump's efforts to secure a meeting with President Xi Jinping this year, the Financial Times said on Monday. The industry and security bureau of the Commerce Department, which oversees export controls, has been told in recent months to avoid tough moves on China, the newspaper said, citing current and former officials. Reuters could not immediately verify the report. The White House and the department did not respond to Reuters' requests for comment outside business hours. Top U.S. and Chinese economic officials are set to resume talks in Stockholm on Monday to tackle longstanding economic disputes at the centre of a trade war between the world's top two economies. Tech giant Nvidia said this month it would resume sales of its H20 graphics processing units (GPU) to China, reversing an export curb the Trump administration imposed in April to keep advanced AI chips out of Chinese hands over national security concerns. The planned resumption was part of U.S. negotiations on rare earths and magnets, Commerce Secretary Howard Lutnick has said. The paper said 20 security experts and former officials, including former deputy US national security adviser Matt Pottinger, will write on Monday to Lutnick to voice concern, however. "This move represents a strategic misstep that endangers the United States' economic and military edge in artificial intelligence," they write in the letter, it added.
Yahoo
19 minutes ago
- Yahoo
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
– Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – SOUTH SAN FRANCISCO, Calif., July 28, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. "Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition." Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. "Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis," said Matt Sause, CEO of Roche Diagnostics. "Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families." Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Pharmaceuticals In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Diagnostics Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm - 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm - 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm - 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm - 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am - 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley About trontinemab Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. About Roche in Alzheimer's Disease With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact: Meghan Hindman (650) 467-6800Advocacy Contact: Jenee Williams (650) 303-2958Investor Contacts: Loren Kalm (650) 225-3217Bruno Eschli +41616875284 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
19 minutes ago
- Yahoo
McDonald's (MCD) Financial Health and Dividend Stability for Food Investors
McDonald's Corporation (NYSE:MCD) is included among the 10 Best Food Stocks with Dividends. A cook in a busy kitchen assembling cheeseburgers for orders. McDonald's Corporation (NYSE:MCD) has evolved significantly since its peak in the mid-20th century, making ongoing efforts to stay current in a rapidly changing restaurant landscape. Despite some recent softness in sales, the company has managed to remain relevant. It's also favored by investors for its reliable dividend, having raised its payout every year since the mid-1970s— earning it Dividend King status. With a payout ratio near 60% of earnings, the company is well-positioned to sustain its dividend. McDonald's Corporation (NYSE:MCD) is prioritizing digital platforms, delivery services, and drive-thru operations to drive future sales growth. By enhancing its mobile app, expanding its loyalty program, and teaming up with third-party delivery providers, the company is working to lead in the delivery space while streamlining the ordering experience for customers. On July 23, McDonald's Corporation (NYSE:MCD) declared a quarterly dividend of $1.77 per share, which was in line with its previous dividend. The company has been growing its payouts for 48 consecutive years, which makes it one of the best food stocks with dividends. The stock has a dividend yield of 2.37%, as of July 27. While we acknowledge the potential of MCD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data